Kuftinec Gabriela, Loehfelm Thomas, Corwin Michael, Durbin-Johnson Blythe, Candido MarieChristi, Hluhanich Rebecca, Sarkar Souvik
Department of Internal Medicine,University of California Davis, 4150 V St, PSSB 3100, Sacramento, CA 95817, USA.
Department of Radiology, University of California Davis, 4860 Y Street, Suite 3100, Sacramento, CA 95817, USA.
Hepat Oncol. 2018 Jul 25;5(1):HEP06. doi: 10.2217/hep-2018-0003. eCollection 2018 Jan.
Recent studies raise concerns for higher incidence of hepatocellular carcinoma (HCC) after direct-acting antiviral therapy for hepatitis C virus (HCV).
In this study, using analysis of liver imaging pre- and post-DAA treatment, we queried new occurrence or '' of HCC in patients with HCV-cirrhosis treated with DAAs. Of 150 patients who met study criteria, 7 (4.7%; 95% CI: 2.1-9.5%) patients developed HCC which did not differ from historical rates of 3% (p = 0.22).
Notably, patients with decompensated cirrhosis had significantly higher rate of HCC (9.3%; 95% CI: 3.12-22.2%; p = 0.04).
Our data support the need for continued surveillance for HCC in HCV cirrhotics even after successful therapy.
近期研究引发了对丙型肝炎病毒（HCV）直接抗病毒治疗后肝细胞癌（HCC）发病率升高的担忧。
在本研究中，通过分析直接抗病毒药物（DAA）治疗前后的肝脏影像学，我们调查了接受DAA治疗的HCV肝硬化患者中HCC的新发病例或“情况”。在150名符合研究标准的患者中，7名（4.7%；95%置信区间：2.1 - 9.5%）患者发生了HCC，这与3%的历史发病率无差异（p = 0.22）。
值得注意的是，失代偿期肝硬化患者的HCC发生率显著更高（9.3%；95%置信区间：3.12 - 22.2%；p = 0.04）。
我们的数据支持即使在成功治疗后，仍需对HCV肝硬化患者持续监测HCC。
